Literature DB >> 2564495

Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes.

R Barker, J Duncan, A Lees.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2564495     DOI： 10.1016/s0140-6736(89)92183-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Ropinirole (SK and F 101468) in the treatment of Parkinson's disease.

Authors:  B Kleedorfer; G M Stern; A J Lees; J M Bottomley; N Sree-Haran
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-10       Impact factor: 10.154

Review 2.  Role of apomorphine in the treatment of Parkinson's disease.

Authors:  Allison Boyle; William Ondo
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 3.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.

Authors:  L Ostergaard; L Werdelin; P Odin; O Lindvall; E Dupont; P B Christensen; E Boisen; N B Jensen; S H Ingwersen; M Schmiegelow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-06       Impact factor: 10.154

5.  The apomorphine test in parkinsonian syndromes.

Authors:  D F D'Costa; R J Abbott; I F Pye; P A Millac
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-10       Impact factor: 10.154

Review 6.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.